Alliance Pharma plc (APH.L) FY 2014 Set for resumption in growth
A solid set of results, demonstrating the resilience of its underlying core businesses.As the company emerges from the loss of its toxicology product the business appears
ready to resume growth with FY 14 underlying pre-tax profit growth having been 15%.
The 2015 acquisition of MacuVision provides an additional franchise upon which to
build. Coupled with a robust balance sheet and the capacity to fund quite significant
opportunities, the outlook for growth looks better than it has done for 3 years.
Alliance Pharma is a holding company. Co. is engaged in the acquisition, marketing and distribution of pharmaceutical and other medical products.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.